In addition, Knight may pay future contingent payments of up to US$15 million upon achieving certain sales milestones. In 2024, Paladin generated revenues of $70 million excluding products that ...

Montreal-based Knight Therapeutics has galloped in with CAD $120 million ($84 million) to pick up Endo’s Paladin Pharma unit in a move that stands to significantly expand its Canadian business.

Knight Therapeutics has agreed to acquire generics and specialty branded pharmaceutical company Paladin Pharma for 120 million Canadian dollars ($83.1 million). The specialty pharmaceutical ...

Davies Ward Phillips & Vineberg LLP; Paladin Pharma Inc. Knight Therapeutics Inc. has entered into a definitive Asset Purchase Agreement (“APA”) with Endo Operations Limited (“Endo”) and Paladin ...